Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629
This examiner grants 52% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18266508 | Compositions and Methods for Inhibiting Fibrosis, Inflammation and Cancer | Non-Final OA | Georgia Tech Research Corporation |
| 17814911 | LOW-CONCENTRATION ATROPINE FOR MYOPIA PREVENTION (LAMP-2) STUDY | Non-Final OA | The Chinese University of Hong Kong |
| 18042503 | CRYSTALLINE FORM OF HETEROBICYCLIC COMPOUND | Final Rejection | OTSUKA PHARMACEUTICAL CO., LTD. |
| 16908426 | OPHTHALMIC COMPOSITION | Final Rejection | SYDNEXIS, INC. |
| 16785411 | OPHTHALMIC COMPOSITION | Final Rejection | SYDNEXIS, INC. |
| 17908684 | METHODS OF SLOWING BRAIN VOLUME LOSS | Final Rejection | Vanda Pharmaceuticals Inc. |
| 18043959 | NOVEL SALTS, CRYSTALS, AND CO-CRYSTALS | Final Rejection | INTRA-CELLULAR THERAPIES, INC. |
| 18007018 | NOVEL USES | Non-Final OA | INTRA-CELLULAR THERAPIES, INC. |
| 18566534 | BENZIMIDAZOLE COMPOUND OR SALT THEREOF, CANINE FILARIASIS CONTROL AGENT CONTAINING SAME, AND METHOD OF USE THEREOF | Non-Final OA | NIHON NOHYAKU CO., LTD. |
| 18506625 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Non-Final OA | Theseus Pharmaceuticals, Inc. |
| 18009194 | 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Final Rejection | IDEAYA BIOSCIENCES, INC. |
| 18555468 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
| 18483703 | METHODS OF TREATING STAPHYLOCOCCUS AUREUS BACTEREMIA INFECTIONS | Non-Final OA | Basilea Pharmaceutica International AG, Allschwil |
| 18549061 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | Non-Final OA | LifeMine Therapeutics |
| 18548804 | MYCOBACTERIUM TUBERCULOSIS COMPOSITIONS AND METHODS | Non-Final OA | PZA INNOVATION LLC |
| 18024159 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | Non-Final OA | CENTESSA PHARMACEUTICALS (UK) LIMITED |
| 18269123 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | Non-Final OA | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd |
| 18255855 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Non-Final OA | Eubulus Biotherapeutics Inc. |
| 17796157 | TREATMENT OF LEUKEMIAS AND LYMPHOMAS WITH COMBINATIONS OF BCL-2 INHIBITORS AND PLK1 INHIBITORS | Non-Final OA | Cardiff Oncology, Inc. |
| 18246977 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | Non-Final OA | Xianlin HAN |
| 18066883 | METHODS OF TREATMENT WITH S1P RECEPTOR MODULATORS | Non-Final OA | PRIOTHERA LIMITED |
| 17923215 | COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES | Non-Final OA | IMCYSE SA |
| 17754321 | Preparation of Drug for Treating Alzheimer's Disease (AD) | Non-Final OA | Plantarx Limited |
| 17635106 | ABIRATERONE PRODRUGS | Non-Final OA | ASTELLAS US LLC |
| 17572896 | COMPOSITIONS AND METHODS FOR TREATING BASAL FOREBRAIN DISEASE | Non-Final OA | EIP Pharma, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy